Literature DB >> 19929178

Regulation of p53--insights into a complex process.

Karen A Boehme1, Christine Blattner.   

Abstract

The p53 protein is one of the most important tumor suppressor proteins. Normally, the p53 protein is in a latent state. However, when its activity is required, e.g. upon DNA damage, nucleotide depletion or hypoxia, p53 becomes rapidly activated and initiates transcription of pro-apoptotic and cell cycle arrest-inducing target genes. The activity of p53 is regulated both by protein abundance and by post-translational modifications of pre-existing p53 molecules. In the 30 years of p53 research, a plethora of modifications and interaction partners that modulate p53's abundance and activity have been identified and new ones are continuously discovered. This review will summarize our current knowledge on the regulation of p53 abundance and activity.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19929178     DOI: 10.3109/10409230903401507

Source DB:  PubMed          Journal:  Crit Rev Biochem Mol Biol        ISSN: 1040-9238            Impact factor:   8.250


  51 in total

1.  MAP/ERK kinase kinase 1 (MEKK1) mediates transcriptional repression by interacting with polycystic kidney disease-1 (PKD1) promoter-bound p53 tumor suppressor protein.

Authors:  M Rafiq Islam; Tamara Jimenez; Christopher Pelham; Marianna Rodova; Sanjeev Puri; Brenda S Magenheimer; Robin L Maser; Christian Widmann; James P Calvet
Journal:  J Biol Chem       Date:  2010-10-05       Impact factor: 5.157

2.  p53 in stem cells.

Authors:  Valeriya Solozobova; Christine Blattner
Journal:  World J Biol Chem       Date:  2011-09-26

3.  Mdm2 facilitates the association of p53 with the proteasome.

Authors:  Roman Kulikov; Justine Letienne; Manjit Kaur; Steven R Grossman; Janine Arts; Christine Blattner
Journal:  Proc Natl Acad Sci U S A       Date:  2010-05-17       Impact factor: 11.205

4.  TRIM25 has a dual function in the p53/Mdm2 circuit.

Authors:  P Zhang; S Elabd; S Hammer; V Solozobova; H Yan; F Bartel; S Inoue; T Henrich; J Wittbrodt; F Loosli; G Davidson; C Blattner
Journal:  Oncogene       Date:  2015-03-02       Impact factor: 9.867

Review 5.  Dysfunction of the TP53 tumor suppressor gene in lymphoid malignancies.

Authors:  Zijun Y Xu-Monette; L Jeffrey Medeiros; Yong Li; Robert Z Orlowski; Michael Andreeff; Carlos E Bueso-Ramos; Timothy C Greiner; Timothy J McDonnell; Ken H Young
Journal:  Blood       Date:  2012-01-24       Impact factor: 22.113

6.  Context-dependent enhancement of induced pluripotent stem cell reprogramming by silencing Puma.

Authors:  Blue B Lake; Jürgen Fink; Liv Klemetsaune; Xuemei Fu; John R Jeffers; Gerard P Zambetti; Yang Xu
Journal:  Stem Cells       Date:  2012-05       Impact factor: 6.277

7.  The RNA surveillance protein SMG1 activates p53 in response to DNA double-strand breaks but not exogenously oxidized mRNA.

Authors:  Jennifer S Gewandter; Robert A Bambara; Michael A O'Reilly
Journal:  Cell Cycle       Date:  2011-08-01       Impact factor: 4.534

Review 8.  Expression of p53 in upper urinary tract urothelial carcinoma.

Authors:  Stephen Mitchell; Erik Mayer; Anup Patel
Journal:  Nat Rev Urol       Date:  2011-08-02       Impact factor: 14.432

Review 9.  Towards an understanding of the role of p53 in adrenocortical carcinogenesis.

Authors:  Jonathan D Wasserman; Gerard P Zambetti; David Malkin
Journal:  Mol Cell Endocrinol       Date:  2011-09-10       Impact factor: 4.102

Review 10.  The Tail That Wags the Dog: How the Disordered C-Terminal Domain Controls the Transcriptional Activities of the p53 Tumor-Suppressor Protein.

Authors:  Oleg Laptenko; David R Tong; James Manfredi; Carol Prives
Journal:  Trends Biochem Sci       Date:  2016-09-23       Impact factor: 13.807

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.